B. García Paredes

Prognostic influence of histopathological regression patterns in rectal adenocarcinoma receiving neoadjuvant therapy.

M. Fernández-Aceñero, C. Díaz del Arco, Lourdes Estrada Muñoz, 2017, Journal of gastrointestinal oncology.

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.

J. G. García Sáenz, E. Díaz Rubio, L. Villalobos, 2007, Medicina oral, patologia oral y cirugia bucal.

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.

M. Ducreux, Jaw-Yuan Wang, J. D. de Groot, 2019, European journal of cancer.

Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.

I. Juez Martel, A. Carmona-Bayonas, M. Sánchez Cánovas, 2019, The oncologist.

Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review

J. G. García Sáenz, J. Bobokova, E. Díaz-Rubio García, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study.

M. Ducreux, J. D. de Groot, J. Metges, 2018, Annals of Oncology.